RA CAPITAL MANAGEMENT L.P. 13D and 13G filings for UroGen Pharma Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 6:13 pm Sale | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -3,206,271 (Position Closed) | Filing |
| 2025-05-15 4:53 pm Unchanged | 2025-03-31 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,206,271 7.000% | 0 (Unchanged) | Filing |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,206,271 7.100% | 122,713 (+3.98%) | Filing |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,558 9.990% | 8 (+0.00%) | Filing |
| 2023-12-29 4:30 pm Purchase | 2023-12-19 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,550 9.990% | 3,083,550 (New Position) | Filing |